Advisory: Give yourself extra time when travelling by car to Toronto General Hospital, Princess Margaret Cancer Centre, or Toronto Rehab University Centre. City of Toronto construction on University Ave. may cause delays.
At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
A UHN study has revealed a new therapeutic approach that could help to treat glioblastoma, the most common and most aggressive form of brain cancer in adults.
In 2017, glioblastoma claimed the life of Gord Downie, the frontman of iconic Canadian rock band, The Tragically Hip.
Glioblastoma is a deadly cancer diagnosed in approximately 1,000 Canadians every year. Less than five per cent of these individuals survive more than five years.
The rates of survival are dismal because most of these brain tumours do not respond to current treatments. New and more effective treatments are therefore urgently needed for this disease.
In the study,
Dr. Valerie Wallace, a Senior Scientist at the Krembil Research Institute, and her trainee, Dr. Ahmed El-Sehemy, discovered that the protein Norrin plays an important role – albeit a complicated one – in the growth and proliferation of glioblastoma tumours.
"Norrin has been implicated in blood vessel formation in the brain, eye and inner ear, and the regulation of brain cell behaviour," Dr. Wallace says. "Our findings indicate that Norrin is present in a wide range of brain tumours and that higher levels of the protein are linked to better patient survival."
Glioblastoma tumours contain a small number of specialized cells known as cancer stem cells, which can give rise to new tumour cells. These stem cells are widely believed to be responsible for the cancer's resistance to treatment and its recurrence. Accordingly, targeting these cells could be the key to treating glioblastoma.
The researchers found that Norrin affects the growth and proliferation of a tumour's cancer stem cells.
In stem cells with high levels of the ASCL1 protein, Norrin promoted cell growth, whereas in cells with low ASCL1 levels, Norrin inhibited growth. Although ASCL1's role in brain cancer is not entirely clear yet, the protein is known to be involved in the generation of brain cells during development.
"Our study reveals an unanticipated role of Norrin in brain cancer progression," Dr. Wallace says. "Norrin could be a potential therapeutic target for glioblastoma tumours and may inform the design of patient-specific treatments."
This work was supported by the Cancer Research Society, the Canadian Institutes of Health Research and the Toronto General & Western Hospital Foundation. Dr. Wallace holds a Tier 1 Canada Research Chair in Retina Regeneration.